Near final height after GnRH agonist treatment in central precocious puberty.
The impact of treatment of central precocious puberty (CPP) with gonadotropin-releasing hormone agonists (GnRHa) on final height remains controversial. We analyzed the long term results of 23 girls with CPP treated with triptorelin or leuprolide. Their "near final height" (NFH) assessed at a bone age of at least 14 years and expressed as SDS, was compared either with predicted height before treatment (PAH) or with parental height (TH). We also compared NFH of 12 girls treated before 8 years of age (7.0 +/- 0.5 yr) with NFH of 11 girls treated after 8 years old (8.5 +/- 0.3 yr). The NFH of the 23 girls (-0.9 +/- 1.0 SDS) was not different either from PAH (-0.85 +/- 1.5 SDS) or from TH (-0.5 +/0.6 SDS). Earlier treated girls reached a NFH (-0.97 +/- 1.0 SDS) not different from later treated girls (-0.91 +/- 1.0 SDS; p = ns) and both groups reached parental height (NFH - TH = -0.44 +/- 1 and -0.09 +/- 0.83 SDS, respectively). In conclusion, our patients, treated either earlier or later, reached a near final height comparable to predicted height and familial target; however, these results might still improve further because the girls have not yet reached their final adult height.
Micillo
M
M
Department of Pediatrics, University Federico II, Naples, Italy.
Salerno
M
M
Officioso
A
A
Perna
E
E
Gasparini
N
N
Pisaturo
L
L
Di Maio
S
S
D001827:Body Height / Q000187:drug effects*; D001846:Bone Development; D001927:Brain Diseases / Q000150:complications*; D002648:Child; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D017329:Triptorelin Pamoate / Q000627:therapeutic use
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide